


# Interim Report

MeVis Medical Solutions AG H1-2022/2023



**MeVis**

# TABLE OF CONTENTS

<b>FOREWORD BY THE BOARD OF MANAGEMENT .....</b>	<b>2</b>
<b>THE MEVIS SHARE.....</b>	<b>4</b>
<b>INTERIM MANAGEMENT REPORT H1 2022/2023.....</b>	<b>5</b>
Preliminary note .....	5
Company Basics .....	5
Structure .....	5
Brief overview of business activities.....	5
Economic Report .....	6
Business performance .....	6
Earnings.....	6
Net assets and financial position.....	7
Opportunity and risk report .....	7
Forecast Report .....	8
<b>BALANCE SHEET .....</b>	<b>9</b>
<b>PROFIT AND LOSS ACCOUNT .....</b>	<b>11</b>
<b>APPENDIX .....</b>	<b>12</b>
Basic information .....	12
General data .....	12
Accounting and valuation methods .....	12
Selected notes to the balance sheet and income statement.....	13
1. Receivables and other assets.....	13
2. Provisions.....	13
3. Liabilities.....	13
4. Deferred income .....	13
5. Revenues .....	13
6. Other operating income .....	14
7. Personnel expenses .....	14
8. Other operating expenses .....	14
9. Relationships with related parties .....	14
Supplementary report .....	14
<b>ASSURANCE OF THE LEGAL REPRESENTATIVE .....</b>	<b>15</b>
<b>DISCLAIMER .....</b>	<b>16</b>

## FOREWORD BY THE BOARD OF MANAGEMENT

*Dear Readers,*

In the first half of the financial year 2022/2023, the Company's revenues amounted to € 8,472 k (previous year: € 8,546 k). Of these revenues, 26 % (previous year: 26 %) were attributable to the sale of licenses, 35 % (previous year: 30 %) to maintenance revenues, and 39 % (previous year: 44 %) to other revenues, which include, among other things, services for and recharges to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) fell from € 3,421 k to € 1,839 k, mainly as a result of the year-on-year increase in personnel expenses and higher expenses for foreign currency translation. € 1,839 k, corresponding to an EBIT margin of 22 %.

The Mammography Diagnostics business unfortunately did not develop as positively in the first half of 2023 as in the first 6 months of the previous year. Fewer licenses were sold in the first half of the year, which is mainly due to the still ongoing delay in the delivery of mammography systems. However, the maintenance business in mammography diagnostics developed more positively. The cooperation with our customer Hologic continues to be very positive and the delay in the delivery of modalities and the sale of our licenses will improve by 2024 at the latest.

The demand for lung cancer screening solutions has also increased in 2023, as expected. Project inquiries regionally, as well as nationally, and the need for lung CAD algorithms are increasing. We feel an increasing demand for commercial use for early detection of lung cancer. Sales have increased by 40 % compared to the previous year, although it must be said that we expected even greater growth. Unfortunately, we have to note that tenders have been delayed and medical approvals in some countries also require a considerable increase in time. The market outlook for nationwide lung cancer screening remains very positive.

The liver surgery solutions segment also developed very positively in the past six months. Following the market launch of MeVis' own software application last year and in addition to the growing services in the field of technical visualizations of the liver, which has been performed by MeVis for many years, we are looking forward positively to the second half of the year.

As we expected, the topic of artificial intelligence is taking up more and more space in medical and industrial software applications. We are significantly engaged in this area in order to keep our applications competitive and to further expand our market position.

After almost three years of the Corona pandemic, it has disappeared from view in many parts of the world and the last nationwide protective measures have been lifted. Normality has also returned to us in recent months. For example, our employees are traveling more and more, customer visits are possible again, trade fairs and congresses are taking place and, for the first time in three years, we were able to welcome shareholders in person at our Annual General Meeting at the Atlantic Hotel Universum in Bremen in March. Some of the changes in work organization and processes that we implemented during the pandemic will remain in place for the long term. Employees have come to appreciate the use of video conferencing, the introduction of digital processes and the additional flexibility that home office can offer them.

The Ukraine-Russia war, which has been preoccupying us since the end of February 2022, has not had any major impact on our business activities to date other than indirect influences on procurement channels and logistics chains. The Executive Board of MeVis Medical Solutions AG continues to support the sanctions initiated against Russia and regularly monitors compliance with them. The Medical Technology sector is currently not sanctioned and at this point in time we only anticipate higher energy prices for the Company and expect price increases and delays in purchasing/procurement and logistics similar to the effects of the Corona pandemic.

At this point in time, we are maintaining our forecast: sales for fiscal year 2022/2023 are now expected to be almost stable compared to the previous year at € 18.0 million to € 18.5 million. In addition to sales with the customer Hologic, only slightly increasing sales revenues are expected in the lung and liver area. We expect a decline in the area of development services. For earnings before interest and taxes (EBIT), we expect a decline

to between € 4.5 million to € 5.0 million. The forecast stability in sales and the simultaneous increase in personnel costs, in addition to a significant negative result from currency translation differences, is the main driver for the EBIT outlook.

Even though the environment remains extremely challenging, I am confident that we will be able to master all new challenges.

As in the past reporting period, the Executive Board will regularly review its expectations in the course of fiscal 2022/2023 on the basis of current business developments.

A handwritten signature in black ink, appearing to read 'Marcus Kirchoff', with a stylized flourish at the end.

Marcus Kirchoff  
Management Board



## THE MEVIS SHARE

AS OF 31.03.2023	
ISIN / WKN / Ticker Symbol	DE000A0LBFE4 / A0LBFE / M3V
Industry assignment	Software / Medical technology
gez. Share capital	€ 1,820,000.00
Number of shares	1,820,000
Last price fixing on 30.09.2022	€ 34.20
Last price fixing on 31.03.2023	€ 35.80
High/low price in 2022/2023	€ 37.20 / € 33.40
Market capitalization	€ 65,156 million
General Standard (Regulated Market)	Frankfurt and Xetra
Over-the-counter	Berlin, Düsseldorf, Munich, Stuttgart
Indexes	CDAX, General All-Share, DAXsector All Software

### SHARE PRICE DEVELOPMENT

The MeVis Medical Solutions AG share price remained stable from October 1, 2022 to March 31, 2023 at an average level of € 35.00. At the beginning of the fiscal year, the share was quoted at € 34.20 and closed at € 35.80 in Xetra trading at the end of March. In the course of the first half of fiscal year 2022/2023, the share's high in Xetra trading was € 37.20 and its low was € 33.40. Compared to € 33.40 at the end of March 31, 2022, the value of the MeVis share has increased by 7 % in twelve months. As of March 31, 2023, the market capitalization thus amounted to approx. € 65 million, taking into account 1,820,000 shares outstanding.

### SHAREHOLDER STRUCTURE AS OF MARCH 31, 2023

As of the balance sheet date, 73.66 % of the total share capital of MeVis Medical Solutions AG was held by Varex Imaging Deutschland AG, an indirect subsidiary of Varex Imaging Corporation, Salt Lake City, Utah, USA. According to the shareholder notifications we received, another institutional shareholder is HANSAINVEST Hanseatische Investment-GmbH, which holds approx. 12.57 % of the total share capital of MeVis Medical Solutions AG. This means that around 13.77 % of the shares are in free float.

### COMPENSATION PAYMENT

The control and profit and loss transfer agreement between Varex Imaging Deutschland AG and MMS AG obliges Varex Imaging Deutschland AG to pay a recurring cash payment ("compensation payment") to the outside shareholders for each full financial year for the duration of this agreement. This amounts to € 1.13 (gross) or € 0.95 (net) per share for each full financial year.

# INTERIM MANAGEMENT REPORT H1 2022/2023

## PRELIMINARY NOTE

This report covers the first half of fiscal year 2022/2023, i.e. the reporting period from October 1, 2022 to March 31, 2023. The prior-year amounts stated below relate to the first half of fiscal year 2021/2022 from October 1, 2021 to March 31, 2022. MeVis Medical Solutions AG prepared its annual financial statements for fiscal year 2021/2022 in accordance with the provisions of the German Commercial Code applicable to corporations and in compliance with the German Stock Corporation Act. These interim financial statements have also been prepared on this basis.

## COMPANY BASICS

### STRUCTURE

MeVis Medical Solutions AG (hereinafter also referred to as "MMS AG", "MeVis" or the "Company") was founded in 1997 and commenced operations in 1998. 73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. A control and profit and loss transfer agreement is in place between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. Thus, MMS AG belongs via Varex Imaging Deutschland AG to the Varex Group under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

MMS AG holds 51 % of MeVis BreastCare GmbH & Co. KG, Bremen, (hereinafter also referred to as "MBC" or "MBC KG") as part of a joint venture with Siemens Healthcare GmbH, Munich, (hereinafter also referred to as "Siemens").

### BRIEF OVERVIEW OF BUSINESS ACTIVITIES

MeVis Medical Solutions AG develops innovative software for the acquisition, analysis and evaluation of image data and markets this software to manufacturers of medical devices, providers of medical IT platforms and, to a lesser extent, directly to clinical end customers.

The clinical focus is on image-based early detection and diagnosis of epidemiologically significant diseases, such as breast, lung, liver and neurological diseases. The software solutions support many of the imaging methods used. These include not only X-ray-based radiographic procedures such as computed tomography, mammography or digital tomosynthesis, but also magnetic resonance tomography, digital sonography and the simultaneous use of several procedures (multimodality). MeVis supplies technologies and software applications for global market leaders in the medical sector which meet the demands of these companies for technological leadership and help to expand their position.

In addition to the sale of software licenses and associated maintenance contracts, MeVis also offers software development services for medical technology companies as development services. These comprise project processing by software development teams consisting of software developers, product and project managers, application specialists as well as test engineers. The teams support external customers in the development of software modules or applications and in the integration of new functions and new technologies, such as algorithms based on artificial intelligence. Likewise, services are provided to clinical end users. These include three-dimensional technical visualizations ("MeVis Distant Services"), interactive online training to improve the diagnostic skills of clinicians and internet-based special applications in teleradiology ("MeVis Online Services").

Whereas in the early years of MeVis the focus was on image-based early detection and the diagnosis of breast cancer, today MeVis uses the clinical expertise acquired, the know-how from the field of breast cancer, the innovative software technologies as well as the partner network established for the successive further development of the software solutions to open up new applications in other indications and diseases of other areas of the body. The individual product areas are described in more detail below:

## ECONOMIC REPORT

### BUSINESS PERFORMANCE

The Company's operating business consists of the development and sale of software licenses, the related maintenance business, software development for medical technology companies (development services), and the provision of services for technical visualizations (distant services) and as part of online training.

At around 87 % (previous year: 89 %) of total sales, the software business, which includes products for the medical technology company Hologic, again accounted for the majority of the Company's total sales in this reporting period.

The first half of fiscal year 2022/2023 was again successful for MeVis in terms of key financial figures. The Company continued to participate in Hologic's very good market position for breast cancer screening.

### EARNINGS

In the first half of the year, the Company's revenues amounted to € 8,472 k (previous year: € 8,546 k). Of these revenues, 26 % (previous year: 26 %) were generated from the sale of licenses, 35 % (previous year: 30 %) from maintenance revenues, and 39 % (previous year: 44 %) from other revenues, which include services provided to and recharges made to affiliated companies and the parent company. The slight improvement in maintenance revenue is mainly due to the business with the customer Hologic. The year-on-year deterioration in other revenue is due to a reduction in revenue from development services.

Other operating income amounted to € 626 k in the first half of the year (previous year: € 1,031 k). It mainly comprises income from exchange rate differences amounting to € 568 k (previous year: € 955 k).

The cost of materials increased slightly to € 208 k (previous year: € 194 k). The Company's personnel expenses amounted to € 4,739 k in the first half of the year (previous year: € 4,369 k). In the year under review, the average number of permanent employees of the Company increased by 4 to 108.

Other operating expenses amounted to € 2,834 k in the reporting period (previous year: € 1,586 k). They consist of expenses from exchange rate differences amounting to € 1,739 k (previous year: € 629 k), rental expenses of € 252 k (previous year: € 238 k), expenses for legal, consulting and auditing services of € 217 k (previous year: € 216 k), sales expenses of € 64 k (previous year: € 63 k), and operating expenses of € 129 k (previous year: € 56) and further operating expenses of € 433 k (previous year: € 384 k).

Earnings before interest and taxes (EBIT) fell from € 3,421 k to € 1,839 k, mainly due to the year-on-year increase in personnel expenses and higher expenses from foreign currency translation.

Income from long-term loans amounts to € 624 k (previous year: € 85 k) and relates to interest income from the loan granted to Varex Imaging Deutschland AG, for which an interest rate adjustment was made at the beginning of the financial year. This results in earnings before taxes (EBT) of € 1,893 k (previous year: € 3,463 k).

Income taxes amounting to € 64 k (previous year: € 42 k) were incurred in the past half year. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG amounting to € 1,829 k (previous year: € 3,421 k), the net income for the year amounts to € 0 k (previous year: € 0 k). It should be noted that the expense from the profit and loss transfer does not legally arise until the end of the financial year.

## NET ASSETS AND FINANCIAL POSITION

Total assets decreased to € 24,374 k (September 30, 2022: € 31,201 k). Current assets decreased by € 6,858 k, while equity remained constant. Accruals decreased by € 957 k and liabilities decreased by € 6,057 k. Deferred income increased by € 186 k.

The equity ratio increased to 73 % (September 30, 2022: 57 %) due to the lower balance sheet total and the constant equity, while the debt ratio decreased accordingly to 27 % (September 30, 2022: 43 %).

Current assets decreased by € 6,858 k to € 7,510 k as of the balance sheet date (September 30, 2022: € 14,369 k). This is mainly due to the decrease in trade receivables from € 4,008 k to € 2,083 k and the decrease in cash and cash equivalents (cash on hand, bank balances) from € 9,320 k to € 4,415 k.

The company's equity remained constant at € 17,826 k (September 30, 2022: € 17,826 k) and, in addition to the subscribed capital of € 1,820 k (September 30, 2022: € 1,820 k), comprises the capital reserve of € 11.461 k (September 30, 2022: € 11,461 k) as well as the statutory revenue reserves of € 5 k (September 30, 2022: € 5 k) and the other revenue reserves of € 4,540 k (September 30, 2022: € 4,540 k).

Compared to the previous year, provisions decreased by € 957 k to € 2,747 k (September 30, 2022: € 3.704 k). Pension provisions remained constant. Other provisions decreased to € 2,039 k, partly due to lower personnel provisions. Liabilities decreased by € 6,057 k to € 2,119 k, mainly due to the reduction in liabilities to shareholders as of the balance sheet date (September 30, 2022: € 8,176 k). Deferred income increased by € 186 k to € 1,681 k due to higher customer prepayments for services to be provided by the Company in the future compared to the previous year.

The Company's cash and cash equivalents decreased from € 9,320 k to € 4,415 k in the first half of the year.

Overall, the net assets, financial position and results of operations developed very satisfactorily.

## OPPORTUNITY AND RISK REPORT

There have been no significant changes in the Company's risk situation since the beginning of the financial year. The disclosures made in the report on opportunities and risks in the financial statements as of the end of the financial year ended September 30, 2022 therefore continue to apply.



## FORECAST REPORT

At this point in time, we are sticking to our forecast: despite the Ukraine war and the energy crisis, sales for the financial year 2022/2023 are expected to remain almost stable compared to the previous year at € 18.0 million to € 18.5 million. In addition to sales with the customer Hologic, only slightly increasing sales revenues are expected in the lung and liver area. We expect a decline in the area of development services. For the annual result before profit transfer, interest result and income taxes (EBIT), we expect a decline to between € 4.5 million to € 5.0 million. The forecasted stability in sales and the simultaneous increase in personnel costs, in addition to a significant negative result from exchange rate differences, are the main drivers for the declining outlook for EBIT.

As in the past reporting period, the Executive Board will regularly review its expectations in the course of fiscal 2022/2023 on the basis of current business developments.

Bremen, May 25, 2023



Marcus Kirchoff

Board of Directors

# BALANCE SHEET

of MeVis Medical Solutions AG, Bremen, as of March 31, 2023

<b>ASSETS (FIGURES IN €)</b>	<b>31.03.2023</b>	<b>30.09.2022</b>
<b>A. Fixed assets</b>		
<b>I. Intangible assets</b>		
Concessions, industrial property rights and similar rights and assets acquired for consideration, as well as licenses to such rights and assets	63.69	155.28
<b>II. Property, plant and equipment</b>		
Operating and office equipment	167,957.22	162,024.14
<b>III. Financial assets</b>		
1. Shares in affiliated companies	312,042.00	312,042.00
2. Loans to affiliated companies	16,225,211.69	16,225,211.69
	16,537,253.69	16,537,253.69
	16,705,274.60	16,699,433.11
<b>B. Current assets</b>		
<b>I. Receivables and other assets</b>		
1. Trade receivables	2,083,055.39	4,007,563.19
2. Receivables from affiliated companies	712,138.55	730,066.84
3. Other assets	299,453.49	310,461.67
	3,094,648.03	5,048,091.70
<b>II. Cash on hand, bank balances</b>	4,415,432.88	9,320,474.94
	7,510,080.91	14,368,566.64
<b>C. Prepaid expenses</b>	158,280.38	133,439.67
	24,373,635.89	31,201,439.42

<b>LIABILITIES (IN €)</b>	<b>31.03.2023</b>	<b>30.09.2022</b>
<b>A. Equity</b>		
<b>I. Subscribed capital</b>		
Subscribed capital	1,820,000.00	1,820,000.00
<b>II. Capital reserve</b>	11,461,332.48	11,461,332.48
<b>III. Retained earnings</b>		
1. Legal reserve	5,000.00	5,000.00
2. Other retained earnings	4,539,688.30	4,539,688.30
	<u>4,544,688.30</u>	<u>4,544,688.30</u>
	<u>17,826,020.78</u>	<u>17,826,020.78</u>
<b>B. Provisions</b>		
1. Pension provisions	538,582.55	538,582.55
2. Tax provisions	169,636.03	169,538.59
3. Other accrued liabilities	2,038,726.97	2,995,597.10
	<u>2,746,945.55</u>	<u>3,703,718.24</u>
<b>C. Liabilities</b>		
1. Advance payments received on orders	115,334.84	21,890.14
2. Trade accounts payable	19,526.58	192,564.08
3. Liabilities to affiliated companies Company	1,829,011.71	7,789,047.86
4. Other liabilities	155,304.40	172,831.21
	<u>2,119,177.53</u>	<u>8,176,333.29</u>
<b>D. Prepaid expenses</b>	<u>1,681,492.03</u>	<u>1,495,367.11</u>
	<u>24,373,635.89</u>	<u>31,201,439.42</u>

## PROFIT AND LOSS ACCOUNT

of MeVis Medical Solutions AG, Bremen, for the period from October 1, 2022 to March 31, 2023

INDICATIONS IN €	2022/2023	2021/2022
1. Revenues	8,472,290.14	8,545,962.40
2. Other operating income	625,747.58	1,030,771.90
3. Cost of materials		
a) Cost of purchased goods	35,425.01	33,283.75
b) Expenses for purchased services	<u>173,049.50</u>	<u>160,403.32</u>
	208,484.51	193,687.07
4. Personnel expenses		
a) Wages and salaries	3,971,064.53	3,642,866.96
b) Social security contributions and expenses for pensions and other employee benefits	<u>767,890.53</u>	<u>725,658.15</u>
	4,738,954.56	4,368,525.11
5. Amortization of intangible assets and depreciation of property, plant and equipment	47,521.16	49,777.62
6. Other operating expenses	2,834,330.65	1,586,045.81
7. Income from loans held as financial assets	624,364.47	84,616.42
8. Interest and similar expenses	0.00	0.00
9. Taxes on income and earnings	<u>64,099.60</u>	<u>42,500.00</u>
10. Earnings after taxes	1,829,011.71	3,420,815.11
11. Profit to be transferred under a profit and loss transfer agreement	<u>1,829,011.71</u>	<u>3,420,815.11</u>
12. Result for the period	<u>0.00</u>	<u>0.00</u>

# APPENDIX

of the half-year financial report of MeVis Medical Solutions AG, Bremen,  
as of March 31, 2023

## BASIC INFORMATION

### GENERAL DATA

The registered office of the Company is in Bremen/Germany. The company address is: Caroline-Herschel-Str. 1, 28359 Bremen. MMS AG is entered in the commercial register at Bremen Local Court (HRB 23791 HB).

73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. A control and profit and loss transfer agreement exists between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. Thus, MMS AG belongs via Varex Imaging Deutschland AG to the Varex Group under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

MeVis Medical Solutions AG has prepared its annual financial statements for the fiscal year 2021/2022 in accordance with the provisions of the German Commercial Code applicable to corporations and in compliance with the German Stock Corporation Act. These interim financial statements have also been prepared on this basis. These interim financial statements have not been reviewed or audited in accordance with Section 317 HGB.

### ACCOUNTING AND VALUATION METHODS

In preparing the interim financial statements and determining the comparative figures for the previous year, the same accounting policies were applied as in the 2021/2022 annual financial statements. A detailed description of these methods is published in the notes to the 2021/2022 annual financial statements.



## SELECTED NOTES TO THE BALANCE SHEET AND INCOME STATEMENT

### 1. RECEIVABLES AND OTHER ASSETS

Trade receivables amount to € 2,083 k as of the balance sheet date (September 30, 2022: € 4,008 k) and mainly relate to receivables from the customers Hologic, Adaptiiv and Varian Medical Systems. All receivables have a remaining term of up to one year.

Receivables from affiliated companies relate in the amount of € 36 k (September 30, 2022: € 102 k) to trade with MBC KG and in the amount of € 676 k (September 30, 2022: € 628 k) to trade with Varex Imaging Deutschland AG, Willich, and Varex Imaging Corporation, Salt Lake City, USA.

Other assets amounted to € 299 k as of the balance sheet date (September 30, 2022: € 310 k). These mainly relate to a rent deposit of € 250 k and receivables from a development project.

### 2. PROVISIONS

The other provisions amount to € 2,039 k (September 30, 2022: € 2,996 k). Of these, € 639 k (September 30, 2022: € 664 k) relate to outstanding invoices, € 460 k (September 30, 2022: € 512 k) to the defense of a patent lawsuit, € 318 k (September 30, 2022: € 992 k) to bonus provisions, € 294 k (September 30, 2022: € 268 k) to vacation and overtime provisions, , € 175 k (September 30, 2022: € 175 k) to provisions for warranties and € 155 k (September 30, 2022: € 385 k) to provisions for the 13th salary.

### 3. LIABILITIES

In the reporting period, trade payables decreased by € 173 k and amount to € 20 k as of the reporting date. Liabilities to affiliated companies of € 1,851 k (September 30, 2022: € 7,789 k) relate to the profit transfer based on the existing profit and loss transfer agreement with Varex Imaging Deutschland AG. The liability will not legally arise until the end of the financial year 2022/2023.

### 4. DEFERRED INCOME

This item includes deferred revenue components from multiple-element arrangements that have already been paid but not yet recognized. In addition, payments received under maintenance contracts are deferred to the extent that the corresponding maintenance service has not yet been performed.

### 5. REVENUES

Sales are divided into the following revenue types:

FIGURES IN € K	01.10.2022 - 31.03.2023	01.10.2021 - 31.03.2022
Services (consulting and training)	3,341	3,740
Maintenance (software service contracts)	2,961	2,615
Software and licenses	2,170	2,191
	<b>8,472</b>	<b>8,546</b>

## 6. OTHER OPERATING INCOME

Other operating income amounted to € 626k in the first half of the year (previous year: € 1,031k). Of this amount, € 568k (previous year: € 955k) is mainly attributable to exchange rate differences. The exchange rate differences are due to the fact that the majority of services are invoiced in US dollars and liquidity is also held in US dollars. Due to the fact that the Group is part of the Varex Imaging Group and in line with its corporate policy, no hedging transactions are concluded.

## 7. PERSONNEL EXPENSES

The average number of employees was 113 (prior-year period: 104), of which 108 are permanent employees (prior-year period: 104). This corresponds to an average of 100 full-time equivalents (prior-year period: 95).

## 8. OTHER OPERATING EXPENSES

Other operating expenses amounted to € 2,834 k in the reporting period (previous year: € 1,586 k). They consist of expenses from exchange rate differences amounting to € 1,739 k (previous year: € 629 k), rental expenses of € 252 k (previous year: € 238 k), expenses for legal, consulting and auditing services of € 217 k (previous year: € 216 k), sales expenses of € 64 k (previous year: € 63 k), operating expenses of € 129 k (previous year: € 56 k) and other operating expenses of € 433 k (previous year: € 384 k).

## 9. RELATIONSHIPS WITH RELATED PARTIES

The Company conducts transactions with related parties, which are explained below. These are part of the ordinary course of business and are treated as arm's length transactions.

Related parties include the jointly controlled entities MBC KG and MBC GmbH, Varex Imaging Deutschland AG and, via the latter, the affiliated companies of Varex Group, as well as the Management Board and the Supervisory Board and their close relatives.

The following receivables, liabilities, expenses and income of the Company relate to related parties:

FIGURES IN € K	2022/2023
<b>Parent company</b>	
Receivables (from loans granted)	16,225
Receivables (from services)	192
Liabilities (from profit and loss transfer agreement)	1,829
Income (mainly services and interest income)	476
Expenses (from profit and loss transfer agreement)	1,109
<b>Other affiliated companies</b>	
Receivables (from services)	520
Income (mainly services and interest income)	1,392

## SUPPLEMENTARY REPORT

There were no business transactions of particular significance for the Company after the balance sheet date.

## ASSURANCE OF THE LEGAL REPRESENTATIVE

"To the best of my knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim financial statements of MeVis Medical Solutions AG give a true and fair view of the assets, liabilities, financial position and profit or loss of MeVis Medical Solutions AG, and the interim management report includes a fair review of the development and performance of the business and the position of MeVis Medical Solutions AG, together with a description of the principal opportunities and risks associated with the expected development of MeVis Medical Solutions AG for the remaining months of the financial year."

Bremen, May 25, 2023

MeVis Medical Solutions AG



Marcus Kirchhoff

Sole Management Board

# DISCLAIMER

## FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that are based on management's current estimates of future developments. Such statements are subject to risks and uncertainties that are beyond MeVis Medical Solutions AG's ability to control or estimate precisely, such as future market and economic conditions, the behavior of other market participants, the successful integration of new acquisitions and the actions of government regulators. If any of these or other uncertainties and imponderables materialize, or if the assumptions underlying any of these statements prove incorrect, then actual results may be materially different from those expressed or implied by such statements. MeVis Medical Solutions AG neither intends nor assumes any separate obligation to update any forward-looking statements to reflect events or developments occurring after the date of this report.

## DEVIATIONS FOR TECHNICAL REASONS

For technical reasons (e.g. conversion of electronic formats), there may be differences between the accounting documents contained in this financial report and those submitted to the Federal Gazette. In this case, the version submitted to the Federal Gazette shall be deemed the binding version.

The financial report is also available in English translation; in the event of any discrepancies, the German version shall take precedence over the English translation.

The financial report is already available for download on the Internet at:

<http://www.mevis.de/de/investor-relations/finanzberichte/>

## **MeVis Medical Solutions AG**

Caroline-Herschel-Str. 1  
28359 Bremen  
Germany

Phone +49 421 22495 0  
Fax +49 421 22495 999  
info@mevis.de

[www.mevis.de](http://www.mevis.de)